Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 20/20 | 0.71 |
| ▸ | BACE2 | Q9Y5Z0 | 4/20 | 0.71 |
| ▸ | KCNH2 | Q12809 | 14/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9949298 | 0.91 | BACE1 (0.71) | BACE1BACE2KCNH2 | |
| SCHEMBL9949013 | 0.91 | BACE1 (0.71) | BACE1BACE2KCNH2 | |
| SCHEMBL10140898 | 0.90 | BACE1 (0.84) | BACE1BACE2KCNH2 | |
| SCHEMBL9949109 | 0.83 | BACE1 (0.81) | BACE1BACE2KCNH2 | |
| SCHEMBL9949009 | 0.83 | BACE1 (0.84) | BACE1BACE2KCNH2 | |
| SCHEMBL9948954 | 0.83 | BACE1 (1.00) | BACE1BACE2KCNH2 | |
| SCHEMBL9948711 | 0.82 | BACE1 (0.69) | BACE1BACE2KCNH2 | |
| SCHEMBL10140391 | 0.82 | BACE1 (0.88) | BACE1BACE2KCNH2 | |
| SCHEMBL9950403 | 0.81 | BACE1 (0.67) | BACE1BACE2KCNH2 | |
| SCHEMBL9959936 | 0.81 | BACE1 (0.83) | BACE1BACE2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165346-A1 | Compounds and their use as BACE inhibitors | ASTRAZENECA AB (SE) | 2012-06-28 | — | — | US | disclosed |
| WO-2012087236-A1 | COMPOUNDS AND THEIR USE AS BACE INHIBITORS | ASTRAZENECA AB (SE) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165346-A1 | Compounds and their use as BACE inhibitors | BACE1, BACE2, PSEN1 | BACE1 1/4885BACE2 2/4885KCNH2 4827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.